Amarantus Bioscience Holdings Inc (AMBS)

[Ann1]

In the meantime, more positive 'press' -- http://seekingalpha.com/article/1139911-stem-cell-therapy-companies-underappreciated-outperformers?source=yahoo

"Diseases associated with protein misfolding are dealt with by the promising cell therapy company Amarantus BioScience Inc. (AMBS.OB) centered around its patented therapeutic protein Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF). This naturally-occurring protein corrects protein misfolding, one of the major causes of apoptosis (Programmed Cell Death). By manufacturing MANF and administering it to the body, Amarantus uses a regenerative medicine approach. Amarantus is the primary holder of intellectual property for MANF which demonstrated its superiority in treatment of Parkinson's disease. Any drug that is truly effective against Parkinson's disease will be a huge hit. Other applications of MANF include myocardial infarction, traumatic brain injury and rare orphan diseases.

The company also owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines" that can be the source of additional therapeutic proteins in addition to MANF. Its stock jumped in November 2012 from $0.01 to $0.1 currently after announcement that Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board. This announcement followed the release: Amarantus BioSciences Explores Orphan Drug Strategy Based on MANF Protein Folding. FDA Orphan Drug Act status would loosen regulatory hurdles to bring the drug to market. Getting orphan drug status can give a company several advantages and Amarantus would tremendously enhance its prospects if it obtains Orphan Drug Status on MANF."

Doc Joe KNOWS.